Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Distamab vedotin + carboplatin + bevacizumab for HER2-expressing platinum-sensitive recurrent ovarian cancer after prior PARP inhibitor treatment
ChiCTR2400084761Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of disitamab vedotin, carboplatin and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Objective response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
disitamab vedotincarboplatinbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2400084761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084761.